Johnson & Johnson beat Q1 estimates with adjusted EPS of $2.70 and revenue of $24.1B, up nearly 10% year over year. Cancer drug Darzalex generated $4B and psoriasis treatment Tremfya brought in $1.6B, both topping estimates. Autoimmune drug Stelara fell ~60% to $656M amid biosimilar competition. J&J raised its 2026 revenue forecast to $100.8B and EPS outlook to $11.55.
